Soyunmoron wrote this on seekingalpha, and I kind of agree with them. Not that I don’t feel it will not work in clinical, from all I have read and seen, I feel very strongly it will at this point, as we have already seen with maraviroc; just the way it is tested in preclinical doesn’t match the clinical setup, where the person already has metastasis. RP did take some of the placabo group and move them to leronlimab, with great results (and without chemo I might add), which is closer to clinical. But CCR5 does some many different things with cancer, and his previous preclinical data was focusing too narrow of what leronlimab is capable of. Just my opinion.

Quote:

---

I don't think the particular preclinical data can translate into clinical application. Patients are not pretreated with the drug before their tumor starts like in the mouse preclincal test.

---